Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIMA
- Sponsors TESARO
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2017 According to a TESARO media release, company eliminated the enrollment requirement for a biomarker selected tumor in this trial.
- 27 Mar 2017 According to a TESARO media release, based on the results of NOVA trial company announced the expansion and refinement of PRIMA and QUADRA trials to include a broad patient population.